Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CBO Scores 15% Rebate For All Part D Brand Drugs In Health Care Report

Executive Summary

The Congressional Budget Office has taken proposals for a required rebate on drugs for dual-eligible beneficiaries in Medicare Part D a step further by scoring a 15 percent rebate requirement for all brand drugs in the program
Advertisement

Related Content

Part D Rebates In Crosshairs Of HHS OIG Investigators
Part D Rebates In Crosshairs Of HHS OIG Investigators
House Bill Would Expand Rx Market, But Negatives Draw PhRMA's Protest
House Bill Would Expand Rx Market, But Negatives Draw PhRMA's Protest
House Bill Would Expand Rx Market, But Negatives Draw PhRMA Protest
Health Care Reform Prospects Are All About The Score, Baucus Tells CBO
Health Care Reform Prospects Are All About The Score, Baucus Tells CBO
Changing Part D Donut Hole “A Very Expensive Fix,” Daschle Notes
Changing Part D Donut Hole “A Very Expensive Fix,” Daschle Notes
Waxman to seek Medicaid prices for dual eligbles
Advertisement
UsernamePublicRestriction

Register

PS050460

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel